Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Phase 1 Completed 58 enrolled Rhizen Pharmaceuticals SA

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.

Timeline

Start: 2015-09
Primary completion: 2018-03
Completion: 2018-12-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tenalisib	Small molecule	200 mg	Oral

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Summary

Timeline

Drugs

Indications